Drugs / TFC-003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06177678 | Feb → Sep 2024 | ocular hypertension, open-angle glaucoma | Kukje Pharma | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07662759 | Dec 2025 → Mar 2027 expected | ocular hypertension, open-angle glaucoma | Kukje Pharma | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-18 | Kukje Pharma | Regulatory 국제약품, 3제 복합 녹내장 치료제 ‘TFC-003’ 임상 3상 본격 착수 kukjepharm.co.kr ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-18 | Kukje Pharma | 국제약품, 3제 복합 녹내장 치료제 ‘TFC-003’ 임상 3상 본격 착수 kukjepharm.co.kr ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TFC-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06177678 ↗ |
| Route | Topical | “1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.” NCT06177678 ↗ |